Union européenne - français - EMA (European Medicines Agency)

krka, d.d., novo mesto  - lenalidomide hydrochloride monohydrate - multiple myeloma; myelodysplastic syndromes; lymphoma, follicular; lymphoma, mantle-cell - immunosuppresseurs - multiple myelomalenalidomide krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) est indiqué pour le traitement de patients adultes atteints de traitement préalable de myélome multiple qui ne sont pas éligibles pour une transplantation. lenalidomide krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. mantle cell lymphomalenalidomide krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4. 4 et 5. follicular lymphomalenalidomide krka in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) est indiqué pour le traitement de patients adultes atteints de traitement préalable de myélome multiple qui ne sont pas éligibles pour une transplantation. lenalidomide krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. mantle cell lymphomalenalidomide krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4. 4 et 5. follicular lymphomalenalidomide krka in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Union européenne - français - EMA (European Medicines Agency)

krka, d.d., novo mesto  - lenalidomide hydrochloride monohydrate - multiple myeloma; lymphoma, follicular - immunosuppresseurs - multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) est indiqué pour le traitement de patients adultes atteints de traitement préalable de myélome multiple qui ne sont pas éligibles pour une transplantation. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) est indiqué pour le traitement de patients adultes atteints de traitement préalable de myélome multiple qui ne sont pas éligibles pour une transplantation. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Union européenne - français - EMA (European Medicines Agency)

krka, d.d., novo mesto  - lenalidomide hydrochloride hydrate - multiple myeloma; lymphoma, follicular; myelodysplastic syndromes - immunosuppresseurs - multiple myelomalenalidomide krka d. as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) est indiqué pour le traitement de patients adultes atteints de traitement préalable de myélome multiple qui ne sont pas éligibles pour une transplantation. lenalidomide krka d. in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka d. as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. follicular lymphomalenalidomide krka d. in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Belgique - français - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

teva b.v. - chlorhydrate de lénalidomide hydraté 3,025 mg - eq. lénalidomide 2,5 mg - gélule - 2,5 mg - chlorhydrate de lénalidomide hydraté 3.025 mg - lenalidomide

Belgique - français - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

teva b.v. - chlorhydrate de lénalidomide hydraté 6,05 mg - eq. lénalidomide 5 mg - gélule - 5 mg - chlorhydrate de lénalidomide hydraté 6.05 mg - lenalidomide

Belgique - français - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

teva b.v. - chlorhydrate de lénalidomide hydraté 9,075 mg - eq. lénalidomide 7,5 mg - gélule - 7,5 mg - chlorhydrate de lénalidomide hydraté 9.075 mg - lenalidomide

Belgique - français - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

teva b.v. - chlorhydrate de lénalidomide hydraté 12,1 mg - eq. lénalidomide 10 mg - gélule - 10 mg - chlorhydrate de lénalidomide hydraté 12.1 mg - lenalidomide

Belgique - français - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

teva b.v. - chlorhydrate de lénalidomide hydraté 18,15 mg - eq. lénalidomide 15 mg - gélule - 15 mg - chlorhydrate de lénalidomide hydraté 18.15 mg - lenalidomide

Belgique - français - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

teva b.v. - chlorhydrate de lénalidomide hydraté 24,2 mg - eq. lénalidomide 20 mg - gélule - 20 mg - chlorhydrate de lénalidomide hydraté 24.2 mg - lenalidomide

Belgique - français - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

teva b.v. - chlorhydrate de lénalidomide hydraté 30,25 mg - eq. lénalidomide 25 mg - gélule - 25 mg - chlorhydrate de lénalidomide hydraté 30.25 mg - lenalidomide